Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Elander, N Aughton, K Ghaneh, P Neoptolemos, J Palmer, D Cox, T Campbell, F Costello, E Halloran, C Mackey, J
Elander, N
Aughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Citations
Altmetric:
Abstract
Deoxycytidylate deaminase (DCTD) and ribonucleotide reductase subunit M1 (RRM1) are potential prognostic and predictive biomarkers for pyrimidine-based chemotherapy in pancreatic adenocarcinoma.
Authors
Elander, N
Aughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Büchler, M
Greenhalf, W
Aughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Büchler, M
Greenhalf, W
Affiliation
Cancer Research U.K. Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UK
Description
Date
2018-04
Publisher
Collections
Keywords
Type
Article
Citation
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. 2018, 118(8): 1084-1088 Br J Cancer